EQS-News: NeuroOne Medical Technologies: NeuroOne(R) Achieves Major Milestone With ISO 13485 Certification
NeuroOne Medical Technologies (Nasdaq: NMTC) said it received ISO 13485-2016 certification for its quality management system covering design and development, manufacturing and distribution of electrosurgical generators and instruments, diagnostic neurophysiological devices, and related components. The company said the certification supports international commercialization of its Evo Cortical and Evo sEEG electrodes and OneRF Brain Ablation System, with Zimmer Biomet as distribution partner.
How this was made
The 30-second read
Why it matters
The company frames the certification as a step toward international commercialization and nearer-term revenue potential, including planned work with distribution partner Zimmer Biomet and potential independent distributors for geographies held solely by NeuroOne.
Market read
Traders may view the certification as incremental but tangible progress toward international market access, potentially improving commercialization odds, though without revenue or guidance details.
What to watch
The release does not quantify expected sales ramp, costs, or whether Zimmer Biomet’s distribution plan has already been agreed with commercial terms.
Background
ISO 13485 is the international quality management standard for medical device manufacturers, often required or expected for regulatory and commercial readiness in many markets.
Ticker impact
NeuroOne (NMTC) announced it received ISO 13485-2016 certification, enabling international marketing efforts for its Evo and OneRF systems.
Likely modest positive bias, with follow-through dependent on distribution execution and actual international sales traction.
The article discloses a new certification and links it to near-term revenue potential and distribution planning, but provides no financial figures, guidance, or timeline for revenue realization.
Market effects
Supports the broader medtech theme that quality-system certifications can unlock cross-border commercialization and reduce compliance risk.
No specific regional demand or regulatory change is quantified; impact is primarily company-specific.
ISO 13485 is internationally recognized, so the milestone can matter for global device market access, though the article does not name target countries beyond noting additional requirements may apply.
Counterpoint
Certification alone may not translate into near-term revenue if reimbursement, clinical adoption, or distribution capacity are the binding constraints.
Key entities
- CompanyNeuroOne Medical Technologies Corporation
Nasdaq-listed medical technology company announcing ISO 13485-2016 certification to support international commercialization of its electrode and brain ablation products.
- Distribution partnerZimmer Biomet
Named as the distribution partner NeuroOne will work with to plan market entry for short-term paths to commercialization.
- Regulatory/quality standardISO 13485-2016
International medical device quality management system standard; certification indicates compliance with design controls, risk management, and traceability requirements.
